The Patent Finder

Alivus Life Sciences Limited

14 patents currently held · Updated Nov 16, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Previously recorded as Glenmark Life Sciences Limited (to 2025)

1
Ending by 2030
Jan 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Apr 29, 2027
    The maintenance fee for Process for the preparation of tavaborole (US 10,457,695) comes due Apr 29, 2027. Unpaid by Oct 29, 2027, it lapses early.
  • 1 fee due Jun 3, 2027
    The maintenance fee for Process for the preparation of apremilast (US 10,494,342) comes due Jun 3, 2027. Unpaid by Dec 3, 2027, it lapses early.
  • 1 fee due Jul 5, 2027
    The maintenance fee for Amorphous and crystalline forms of aprepitant and processes for the preparation thereof (US 9,227,958) comes due Jul 5, 2027. Unpaid by Jan 5, 2028, it lapses early.
  • 1 fee due Aug 11, 2027
    The maintenance fee for Process for preparation of dapagliflozin (US 10,556,877) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 18, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,097,729Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,227,958Amorphous and crystalline forms of aprepitant and processes for the preparation thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,670,160Process for the preparation of tofacitinib and intermediates thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,550,735Process for the preparation of ivacaftor and solvates thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,840,456Process for preparation of dimethyl fumarate
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,556,877Process for preparation of dapagliflozin
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,494,342Process for the preparation of apremilast
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,457,695Process for the preparation of tavaborole
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,447,448Process for the preparation of solriamfetol and salt thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,365,649Process for the preparation of brivaracetam
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 14 patents shown.
Pro members see all 14.
Pro members: see all 14 patents
Also on record, not counted in the 14: 1 lapsed for an unpaid fee · 1 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited